Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”

T cell-based immunotherapy has demonstrated great therapeutic potential in recent decades, on the one hand, by using tumor-infiltrating lymphocytes (TILs) and, on the other hand, by engineering T cells to obtain anti-tumor specificities through the introduction of either engineered T cell receptors...

Descripción completa

Detalles Bibliográficos
Autores principales: Teppert, Karin, Wang, Xueting, Anders, Kathleen, Evaristo, César, Lock, Dominik, Künkele, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739809/
https://www.ncbi.nlm.nih.gov/pubmed/36498890
http://dx.doi.org/10.3390/ijms232314563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739809/
https://www.ncbi.nlm.nih.gov/pubmed/36498890
http://dx.doi.org/10.3390/ijms232314563

Ejemplares similares